Guardant Health, Inc. (NASDAQ:GH – Get Free Report) CFO Michael Brian Bell sold 2,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the completion of the transaction, the chief financial officer owned 47,509 shares of the company’s stock, valued at approximately $6,110,607.58. The trade was a 4.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Michael Brian Bell also recently made the following trade(s):
- On Monday, March 16th, Michael Brian Bell sold 3,000 shares of Guardant Health stock. The stock was sold at an average price of $87.04, for a total value of $261,120.00.
Guardant Health Stock Up 0.4%
Guardant Health stock opened at $130.70 on Thursday. The firm has a market cap of $17.33 billion, a price-to-earnings ratio of -38.55 and a beta of 1.61. Guardant Health, Inc. has a 52 week low of $40.35 and a 52 week high of $134.28. The business’s 50-day moving average price is $101.93 and its 200 day moving average price is $101.75.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Guardant Health
Institutional Trading of Guardant Health
Institutional investors have recently made changes to their positions in the company. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health in the fourth quarter worth approximately $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health in the fourth quarter worth approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health in the fourth quarter worth approximately $31,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health in the fourth quarter worth approximately $35,000. Finally, Parallel Advisors LLC boosted its stake in shares of Guardant Health by 164.7% in the fourth quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock worth $36,000 after acquiring an additional 219 shares during the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.
Guardant Health Company Profile
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Read More
- Five stocks we like better than Guardant Health
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
